Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2019 Filed Jan 7, 2020 17:32 UTC |
Hudson Bay Capital Management LP10% owner
Gerber Sander10% owner
|
PurchaseCommon Stock | 50,000 | $2.99 | $149,500.00 |
DisclosureSEC source: 0001393825-20-000002 · primary_doc.xml · nonDerivative · entry 2 Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner Gerber Sander · CIK 0001416593 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 154,018 F1 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein. Read SEC document |
| December 09, 2019 Filed Jan 7, 2020 17:32 UTC |
Hudson Bay Capital Management LP10% owner
Gerber Sander10% owner
|
PurchaseCommon Stock, no par value ("Common Stock") | 19,353 | $2.96 | $57,284.88 |
DisclosureSEC source: 0001393825-20-000002 · primary_doc.xml · nonDerivative · entry 1 Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner Gerber Sander · CIK 0001416593 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 104,018 F1 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 20:05 UTC |
Yeaton HowardCEO, CFO
|
GrantCommon Stock | 3,750 | $0.42 | $1,560.00 |
DisclosureSEC source: 0001493152-19-014946 · ownership.xml · nonDerivative · entry 1 Yeaton Howard · CIK 0001341910 · CEO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Read SEC document |
| August 30, 2019 Filed Sep 5, 2019 00:49 UTC |
Yeaton HowardCEO, CFO
|
GrantCommon Stock | 3,750 | $0.43 | $1,612.50 |
DisclosureSEC source: 0001493152-19-013695 · ownership.xml · nonDerivative · entry 1 Yeaton Howard · CIK 0001341910 · CEO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,250 Read SEC document |
| July 31, 2019 Filed Aug 1, 2019 13:22 UTC |
Yeaton HowardCEO, CFO
|
GrantCommon Stock | 3,750 | $0.42 | $1,575.00 |
DisclosureSEC source: 0001493152-19-011469 · ownership.xml · nonDerivative · entry 1 Yeaton Howard · CIK 0001341910 · CEO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Read SEC document |
| June 28, 2019 Filed Jun 28, 2019 22:05 UTC |
Yeaton HowardCEO, CFO
|
GrantCommon Stock | 3,750 | $0.45 | $1,695.00 |
DisclosureSEC source: 0001493152-19-009915 · ownership.xml · nonDerivative · entry 1 Yeaton Howard · CIK 0001341910 · CEO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 Read SEC document |
| May 24, 2019 Filed May 30, 2019 20:05 UTC |
Yeaton HowardCEO, CFO
|
GrantCommon Stock | 7,500 | $0.65 | $4,875.00 |
DisclosureSEC source: 0001493152-19-008425 · ownership.xml · nonDerivative · entry 1 Yeaton Howard · CIK 0001341910 · CEO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| March 29, 2019 Filed Mar 29, 2019 23:54 UTC |
Yeaton HowardCEO, CFO
|
GrantCommon Stock | 15,000 | $0.97 | $14,550.00 |
DisclosureSEC source: 0001493152-19-004303 · ownership.xml · nonDerivative · entry 1 Yeaton Howard · CIK 0001341910 · CEO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 21:15 UTC |
White Billy JoeDirector
|
GrantRestricted Stock Units · Derivative | 124,827 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-004747 · ownership.xml · derivative · entry 1 White Billy Joe · CIK 0001546805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,827 Underlying: Common Stock · 124,827 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion. F2 · derivative.exercise_date: Reporting Person was granted 124,827 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), each of which shall vest on January 1, 2020; provided that the RSUs shall vest immediately upon a Change in Control. All capitalized but undefined terms have the meanings ascribed thereto by the Plan. F2 · derivative.expiration_date: Reporting Person was granted 124,827 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), each of which shall vest on January 1, 2020; provided that the RSUs shall vest immediately upon a Change in Control. All capitalized but undefined terms have the meanings ascribed thereto by the Plan. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 21:15 UTC |
Silverman JoshuaDirector
|
GrantRestricted Stock Units · Derivative | 124,827 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-004748 · ownership.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,827 Underlying: Common Stock · 124,827 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion. F2 · derivative.exercise_date: Reporting Person was granted 124,827 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), each of which shall vest on January 1, 2020; provided that the RSUs shall vest immediately upon a Change in Control. All capitalized but undefined terms have the meanings ascribed thereto by the Plan. F2 · derivative.expiration_date: Reporting Person was granted 124,827 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), each of which shall vest on January 1, 2020; provided that the RSUs shall vest immediately upon a Change in Control. All capitalized but undefined terms have the meanings ascribed thereto by the Plan. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 21:15 UTC |
Schreiber Christopher CDirector
|
GrantRestricted Stock Units · Derivative | 124,827 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-004746 · ownership.xml · derivative · entry 1 Schreiber Christopher C · CIK 0001750076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,827 Underlying: Common Stock · 124,827 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion. F2 · derivative.exercise_date: Reporting Person was granted 124,827 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), each of which shall vest on January 1, 2020; provided that the RSUs shall vest immediately upon a Change in Control. All capitalized but undefined terms have the meanings ascribed thereto by the Plan. F2 · derivative.expiration_date: Reporting Person was granted 124,827 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), each of which shall vest on January 1, 2020; provided that the RSUs shall vest immediately upon a Change in Control. All capitalized but undefined terms have the meanings ascribed thereto by the Plan. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 22:00 UTC |
Yeaton HowardCEO, CFO
|
GrantCommon Stock | 7,500 | $1.27 | $9,525.00 |
DisclosureSEC source: 0001493152-19-000042 · ownership.xml · nonDerivative · entry 1 Yeaton Howard · CIK 0001341910 · CEO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Read SEC document |
| October 17, 2017 Filed Oct 24, 2017 20:54 UTC |
RAUCH GARY MVP - Finance, Treasurer
|
GrantCommon Stock | 36,277 | $0.88 | $31,923.76 |
DisclosureSEC source: 0001493152-17-011994 · form4.xml · nonDerivative · entry 1 RAUCH GARY M · CIK 0001597530 · VP - Finance, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,777 F1 · shares: On October 17, 2017, the Board of Directors of Akers Biosciences, Inc. approved the issuance of 36,277 restricted shares of common stock to the reporting person pursuant to the Akers Biosciences, Inc. 2017 Equity Incentive Plan Read SEC document |
| October 17, 2017 Filed Oct 24, 2017 20:50 UTC |
Gormally John JDirector · Chief Executive Officer
|
GiftCommon Stock | 150,000 | $0.88 | $132,000.00 |
DisclosureSEC source: 0001493152-17-011992 · form-4.xml · nonDerivative · entry 1 Gormally John J · CIK 0001661118 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 F1 · shares: On October 17, 2017, the Board of Directors of Akers Biosciences, Inc. approved the issuance of 150,000 restricted shares of common stock to the reporting person pursuant to the Akers Biosciences, Inc. 2017 Equity Incentive Plan. Read SEC document |
| October 17, 2017 Filed Apr 11, 2018 00:42 UTC Amendment |
Gormally John JDirector · Chief Executive Officer
|
GrantCommon Stock | 150,000 | $0.88 | $132,000.00 |
DisclosureSEC source: 0001493152-18-005018 · form4a.xml · nonDerivative · entry 1 Gormally John J · CIK 0001661118 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 F1 · shares: On October 17, 2017, the Board of Directors of Akers Biosciences, Inc. approved the issuance of 150,000 restricted shares of common stock to the reporting person pursuant to the Akers Biosciences, Inc. 2017 Equity Incentive Plan. Read SEC document |
| September 02, 2016 Filed Feb 13, 2017 22:35 UTC |
KNOX BRANDON THOMASDirector
|
GiftCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-17-001449 · form5.xml · nonDerivative · entry 1 KNOX BRANDON THOMAS · CIK 0001597635 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,326 F1 · shares: Such shares were a bona fide gift. No consideration was received. Read SEC document |
| June 08, 2016 Filed Apr 11, 2018 00:40 UTC Amendment |
Gormally John JDirector · Chief Executive Officer
|
GrantCommon Stock | 27,500 | $1.99 | $54,725.00 |
DisclosureSEC source: 0001493152-18-005016 · form4a.xml · nonDerivative · entry 1 Gormally John J · CIK 0001661118 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: On June 8, 2016 Mr. Gormally was issued 27,500 shares of common stock (the "Shares") under the Company's 2013 Incentive Stock and Award Plan, as amended. Pursuant to the Restricted Stock Agreement between Mr. Gormally and the Company governing the issuance of the Shares, 9,167 of the Shares vested on June 8, 2016, 9,167 of the Shares will vest on March 1, 2017, and 9,166 of the Shares will vest on March 1, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.